Haptoglobin, in Visit Clinic

Haptoglobin is a plasma glycoprotein that binds free hemoglobin released during red blood cell breakdown, forming complexes cleared by macrophage receptors. This prevents oxidative tissue and kidney damage, conserves iron for reuse, and limits inflammation. Haptoglobin is an acute‑phase protein whose levels rise in inflammation and fall during intravascular hemolysis, making it a useful clinical marker.

Haptoglobin binds free hemoglobin released into plasma during intravascular hemolysis, forming complexes cleared by the reticuloendothelial system. This prevents hemoglobin-mediated oxidative damage and renal injury. Serum haptoglobin levels fall when hemolysis consumes haptoglobin, so measurement helps detect and monitor intravascular hemolytic anemia and gauge its severity and response to treatment.

Low haptoglobin usually signals increased intravascular hemolysis: free hemoglobin released from red cells binds and depletes haptoglobin, causing low plasma levels. Clinically this associates with hemoglobinuria, jaundice, raised LDH and indirect bilirubin, and risk of kidney injury. Other causes include reduced liver synthesis. Evaluation includes CBC, reticulocyte count, peripheral smear and hemolysis markers to identify the cause and guide treatment.

Haptoglobin is not a specific tumor marker. It is an acute‑phase protein that binds free hemoglobin; levels rise with inflammation and infection and fall with hemolysis. Although altered haptoglobin levels or glycoforms have been reported in some cancers, it lacks the sensitivity and specificity for routine cancer diagnosis or screening. Clinicians interpret haptoglobin in the context of clinical findings and other tests.

To raise haptoglobin, treat the underlying cause: stop or correct hemolysis (remove offending drugs, manage autoimmune hemolytic anemia with appropriate immunosuppression or transfusion), control infections and inflammation, and optimize liver health so the liver can synthesize haptoglobin. Address nutritional deficiencies and follow physician-guided therapies; monitoring and specialist evaluation help ensure targeted treatment.

Yes—haptoglobin can be low in liver disease because the liver produces it, and impaired hepatic synthesis lowers levels. However, haptoglobin is also an acute‑phase protein and may be normal or elevated with inflammation. Low haptoglobin isn’t specific for liver disease and commonly indicates hemolysis; interpret it with bilirubin, LDH, reticulocyte count and the clinical picture.